share_log

D. Boral Capital Initiates Coverage On Lineage Cell Therapeutics With Buy Rating, Announces Price Target of $3

Benzinga ·  Nov 18, 2024 10:12  · Ratings

D. Boral Capital analyst Jason Kolbert initiates coverage on Lineage Cell Therapeutics (AMEX:LCTX) with a Buy rating and announces Price Target of $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment